It was a great pleasure to see so many of you there, pease fill in the survey and your certificate of attendance will be available by the beginning of November

Thank you for attending our 2022 Event

Interested in running eSeminars with the ESGCT?

More Info on our packages

Become an ESGCT member

JOIN NOW

Human Gene Therapy

Log into the Society journal and enjoy reduced submission fees

Outstanding Achievement Award

Prof. Christof von Kalle and Dr Manfred Schmidt

Interested in joining the ESGCT Board?

If you are an academic member check out the criteria and send us your CV

Awards

Nominate your favourite Young Investigator

ESGCT would like to express its sadness and dismay at the loss of Dr. Manfred Schmidt. Manfred passed away on 13th January 2022, age 54. We extend our thoughts and condolences to his family, friends and colleagues.

Dr. Manfred Schmidt was a pioneer in the gene and cell therapy field, with more than 25 years experience in the sector. He was the Co-Founder and CEO of GeneWerk GmbH, based in Heidelberg, Germany. His most recent academic role was the Section Head of Molecular and Gene Therapy at the German Cancer Research Center, also part of the National Center for Tumor Diseases in Heidelberg, Germany.

Manfred obtained his doctoral degree from University of Freiburg, and a Diploma degree in Biology in University Hohenheim, Germany. He authored more than 120 peer-reviewed publications in international high-impact journals.... MORE

Latest News

ESGCT 2022 Award Winners

First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy

New European Consortium - AGORA - launches to ensure access to life-saving gene therapies for children with rare diseases

In memory of Dr. Manfred Schmidt

ERC Horizon Europe 2023 Submission Dates

Review on ex vivo HSC gene therapy for Nature Rev Genetics

Educational Resource: New Horizons in the Management of ADA-SCID

Obituary Notice: Professor Shigetaka Asano

Online Resource: New Horizons in the Management of ADA-SCID

VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan

This week in gene and cell therapy - 26 July 2019

This week in gene and cell therapy - 19 July 2019

This week in gene and cell therapy - 12 July 2019

This week in gene and cell therapy - 5 July 2019

This week in gene and cell therapy - 28 June 2019

VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office

This week in gene and cell therapy - 21 June 2019

This week in gene and cell therapy - 7 June 2019

This week in gene and cell therapy - 31 May 2019

This week in gene and cell therapy - 24 May 2019

This week in gene and cell therapy - 17 May 2019

This week in gene and cell therapy - 10 May 2019

This week in gene and cell therapy - 3 May 2019

This week in gene and cell therapy - 26 April 2019

This week in gene and cell therapy - 12 April 2019

This week in gene and cell therapy - 5 April 2019

John Bell and Lisa Riedmayr win inaugural ESGCT PPE Award

This week in gene and cell therapy - 8 March 2019

This week in gene and cell therapy - 22 February 2019

This week in gene and cell therapy - 15 February 2019

This week in gene and cell therapy - 1 February 2019

This week in gene and cell therapy - 25 January 2019

This week in gene and cell therapy - 18 January 2019

This week in gene and cell therapy - 4 January 2019

This week in gene and cell therapy - 14 December 2018

This week in gene and cell therapy - 7 December 2018

Consensus statement of European Societies of Gene and Cell Therapy on the reported birth of genome-edited babies in China

This week in gene and cell therapy - 23 November 2018

This week in gene and cell therapy - 16 November 2018

This week in gene and cell therapy - 9 November 2018

This week in gene and cell therapy - 2 November 2018

This week in gene and cell therapy - 7 September 2018

This week in gene and cell therapy - 31 August 2018

This week in gene and cell therapy - 24 August 2018

This week in gene and cell therapy - 10 August 2018

This week in gene and cell therapy - 20 July 2018

This week in gene and cell therapy - 13 July 2018

This week in gene and cell therapy - 6 July 2018

This week in gene and cell therapy - 22 June 2018

This week in gene and cell therapy - 15 June 2018

This week in gene and cell therapy - 8 June 2018

This week in gene and cell therapy - 1 June 2018

This week in gene and cell therapy - 25 May 2018

This week in gene and cell therapy - 18 May 2018

This week in gene and cell therapy - 4 May 2018

This week in gene and cell therapy - 27 April 2018

This week in gene and cell therapy - 20 April 2018

This week in gene and cell therapy - 6 April 2018

Promising results of stem cell therapy for MS

This week in gene and cell therapy - 9 March 2018

This week in gene and cell therapy - 16 February 2018

This week in gene and cell therapy - 2 February 2018

This week in gene and cell therapy - 19 January 2018

This week in gene and cell therapy - 12 January 2018

This week in gene and cell therapy - 5 January 2018

2017 breakthroughs in medicine dominated by gene and cell therapy

FDA approved Luxturna, a gene therapy product for inherited blindness

This week in gene and cell therapy - 8 December 2017

This week in gene and cell therapy - 1 December 2017

This week in gene and cell therapy - 24 November 2017

This week in gene and cell therapy - 3 November 2017

This week in gene and cell therapy - 27 October 2017

New base editor extends machinery to correct single base pair mutations

First FDA approval for CAR-T cell therapy

First report of JCAR017 trial: CAR-T cell activity observed in the brain

Gene addition of micro-dystrophin improves Duchenne muscular dystrophy symptoms in dogs

Proof of concept for new strategy of genome editing to correct splice-site mutations

Step forward for precision medicine - personalised anti-cancer vaccine tested in patients

Genome editing used to treat Huntington's disease in mice

Using genome editing to treat chronic inflammation

New genome editing resources for patients and families

First report from diabetes islet transplantation trial NCT02213003

First clinical trial with in vivo genome editing

Phase I trial of gene therapy for age-related macular degeneration completed

ESGCT welcomes two Student Board Members

Feng Zhang Discusses CRISPR and Future of Gene Editing in Interview in Human Gene Therapy

View All

Upcoming Events

6 Nov 2024

Review article: Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

6 Nov 2024

This week in gene and cell therapy - 9 February 2018

View All

Jobs & Courses

JOB

Postdoctoral fellowship at the University of Pennsylvania

JOB

Research Fellow position, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.

JOB

Laboratory Head, The Division of Cell- and Gene Therapy, University of Zurich

JOB

(Associate / Senior) Director, Immunology of Virus-Host Interactions, Vector BioPharma AG, Basel

View All

It was a great pleasure to see so many of you there, pease fill in the survey and your certificate of attendance will be available by the beginning of November

Interested in running eSeminars with the ESGCT?

Become an ESGCT member

Researchers

Students

Sponsors

Public and Patients

Human Gene Therapy

Outstanding Achievement Award

Interested in joining the ESGCT Board?

Awards

Latest News

Upcoming Events

Jobs & Courses

Home

Cookies

Privacy Policy

Terms and Conditions abstract submission

Terms and Conditions congress registration

Terms and Conditions membership purchase

Terms and Conditions user account

Researchers

Students

Sponsors

Public and Patients

Human Gene Therapy

Outstanding Achievement Award

Interested in joining the ESGCT Board?

Awards

Latest News

Upcoming Events

Jobs & Courses

Sponsors

GOLD

SILVER

SUPPORTER

Home

Cookies

Privacy Policy

Terms and Conditions abstract submission

Terms and Conditions congress registration

Terms and Conditions membership purchase

Terms and Conditions user account